DUBLIN, Jan. 17, 2020 /PRNewswire/ -- Allergan plc (NYSE:
AGN) announced today the launch of the SkinMedica®
Instant Bright Eye Cream, a refreshing eye treatment that hydrates,
brightens and helps visibly firm the appearance of the delicate
skin around the eyes. The product is designed to immediately
improve the appearance of the eyes and continues reducing the
visible signs of aging and fatigue over time—including dark
circles, fine lines and crepiness of upper eyelids. For its
most comprehensive regimen, SkinMedica® is also
introducing Instant Bright Eye Mask, a set of hydrogel eye patches
that reduce the appearance of puffiness and provide a hydrating
boost for under the eyes.
"We know from the Allergan 360° Aesthetics Report™
that globally, women state the eye area as a top concern.* By
harnessing the key ingredients from two of our most popular
products, Lytera® 2.0 Pigment Correcting Serum and
HA5® Rejuvenating Hydrator, and pairing them with new
technology, we created a new and unique product that addresses this
top concern," says Carrie Strom,
Senior Vice President of U.S. Medical Aesthetics. "We are committed
to providing physicians and consumers with one-of-a-kind products
backed by science and research to reveal a visible difference. Skin
health is one of the most important investments we can make, and we
are committed to developing innovative products that deliver
impactful results."
The cream was clinically reported to show visible results within
15 minutes of application. Additionally, 95% of patients reported
satisfaction at eight weeks and continued satisfaction at twelve
weeks, reporting that their eyes looked brighter, refreshed and
less tired (n=41).
"Photodamage, oxidative stress, and lifestyle factors all affect
the delicate skin around the eyes and can cause this area to look
tired and dull. Aging skin only exacerbates the problem and these
concerns become more prominent over time," says Dr. Suneel Chilukuri, Houston-based board-certified dermatologist.
"In the double-blind, placebo-controlled clinical study, various
skin types were included to ensure that the product could help
brighten, hydrate and protect the skin, regardless of skin color
and textures."
For nearly two decades, SkinMedica® innovations have
changed the face of skincare and are a leading choice of physicians
and their patients. Instant Bright Eye Cream is now available in
participating physicians' offices for $88 MSRP and Instant Bright Eye Masks for
$48 MSRP. To find an authorized
skincare provider, please visit www.SkinMedica.com. Instant Bright
products will be available for purchase online at
www.SkinMedica.com beginning April
2020.
*Data on file, Allergan 360° Aesthetics Report™. April 2019.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers, and patients to deliver
innovative and meaningful treatments that help people around the
world live longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2018
and Allergan's Quarterly Report on Form 10-Q for the period ended
September 30, 2019. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7488
Media:
Ember Garrett
(714) 246-3525
Kaetlyn Boone
(714) 330-6483
View original content to download
multimedia:http://www.prnewswire.com/news-releases/skinmedica-launches-new-instant-bright-eye-cream-for-immediate-visible-results-300988701.html
SOURCE Allergan plc